PDF(1235 KB)
儿童急性淋巴细胞白血病化疗相关严重不良反应的临床分析
许凤玲, 管贤敏, 温贤浩, 沈亚莉, 肖剑文, 郭玉霞, 邓梦月, 于洁
中国当代儿科杂志 ›› 2020, Vol. 22 ›› Issue (8) : 828-833.
PDF(1235 KB)
PDF(1235 KB)
儿童急性淋巴细胞白血病化疗相关严重不良反应的临床分析
Serious adverse events associated with chemotherapy in children with acute lymphoblastic leukemia
目的 分析CCCG-ALL-2015方案治疗儿童急性淋巴细胞白血病（ALL）合并严重不良反应（SAE）的临床特点，探讨患儿发生SAE后死亡的危险因素。方法 回顾性分析2015年1月至2019年6月确诊并接受CCCG-ALL-2015方案化疗的734例ALL患儿化疗过程中发生SAE的临床特点，将发生SAE的ALL患儿分为死亡组（n=25）和存活组（n=31），采用多因素logistic回归分析ALL患儿发生SAE后死亡的危险因素。结果 734例ALL患儿中，56例（7.6%）化疗后发生SAE（66例次），高发于诱导缓解治疗阶段（41例次）。感染相关SAE发生46例次（70%），包括脓毒性休克25例次（38%），重症肺炎20例次（30%），重症水痘1例次（2%）；感染相关SAE患儿中多数存在中性粒细胞缺乏（87%）。最常见的感染部位为血液系统和呼吸系统，最常见的病原微生物依次是革兰阴性菌、病毒、真菌和革兰阳性菌。出血相关SAE发生16例次（24%），包括消化道出血11例次（17%），肺出血4例次（6%），颅内出血1例次（2%）。734例ALL患儿中死亡66例（9.0%），25例患儿因SAE死亡，治疗相关病死率为3.4%，感染（72%）和出血（24%）是主要原因，合并重症肺炎是ALL患儿发生治疗相关死亡的独立危险因素（OR=4.087，95% CI：1.161~14.384，P=0.028）。结论 CCCG-ALL-2015方案治疗儿童ALL相关SAE主要发生于诱导缓解化疗阶段，感染相关SAE较多见。重症肺炎是ALL患儿发生治疗相关死亡的独立危险因素，需重视合并重症肺炎的治疗。
Objective To study the occurrence of serious adverse events (SAEs) related to chemotherapy with CCCG-ALL-2015 regimen in children with acute lymphoblastic leukemia (ALL) and the risk factors for death after the SAEs. Methods A retrospective analysis was performed on the medical data of 734 children with ALL. They were treated with CCCG-ALL-2015 regimen from January 2015 to June 2019. The occurrence of SAEs during the treatment was investigated. The children with SAEs were divided into a death group with 25 children and a survival group with 31 children. A multivariate logistic regression analysis was used to analyze the risk factors for death after the SAEs. Results Among the 734 children with ALL, 56 (7.6%) experienced SAEs (66 cases) after chemotherapy, among which 41 cases occurred in the stage of remission induction therapy. Of all 66 cases of SAEs, 46 (70%) were infection-related SAEs, including 25 cases of septic shock (38%), 20 cases of severe pneumonia (30%), and 1 case of severe chickenpox (2%), and 87% of the children with infection-related SAEs had neutrophil deficiency. The most common infection sites were blood and the lungs. The most common pathogens were Gram-negative bacteria, viruses, fungi, and Gram-positive bacteria. There were 16 cases (24%) of hemorrhage-related SAEs, with 11 cases of gastrointestinal bleeding (17%), 4 cases of pulmonary bleeding (6%), and 1 case of intracranial bleeding (2%). Of all 734 children with ALL, 66 (9.0%) died, among whom 25 died due to SAEs. The treatment-related mortality rate was 3.4%, and infection (72%) and bleeding (24%) were the main causes of death. Severe pneumonia was an independent risk factor for treatment-related death in ALL children (OR=4.087, 95% CI: 1.161-14.384, P=0.028). Conclusions SAEs often occur in the stage of remission induction therapy, and infection-related SAEs are more common in ALL children accepting chemotherapy with CCCG-ALL-2015 regimen. The development of severe pneumonia suggests an increased risk for death in these children.
急性淋巴细胞白血病 / 严重不良反应 / 治疗相关死亡 / 儿童
Acute lymphoblastic leukemia / Severe adverse event / Treatment-related mortality / Child
[1] 王建祥. 急性淋巴细胞白血病[M]//沈悌, 赵永强. 血液病诊断及疗效标准. 第4版. 北京:科学出版社, 2018:110-119.
[2] National Cancer Institute. SEER cancer statistics review 1975-2017[EB/OL].[2020-03-20]. https://seer.cancer.gov/csr/1975_2017/browse_csr.php?sectionSEL=28&pageSEL=sect_28_table.08.
[3] O'Connor D, Bate J, Wade R, et al. Infection-related mortality in children with acute lymphoblastic leukemia:an analysis of infectious deaths on UKALL2003[J]. Blood, 2014, 124(7):1056-1061.
[4] Pui CH, Pei D, Campana D, et al. A revised definition for cure of childhood acute lymphoblastic leukemia[J]. Leukemia, 2014, 28(12):2336-2343.
[5] Cui L, Li ZG, Chai YH, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008:the first nation-wide prospective multicenter study in China[J]. Am J Hematol, 2018, 93(7):913-920.
[6] Shen S, Chen X, Cai J, et al. Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia:a randomized clinical trial[J]. JAMA Oncol, 2020, 6(3):358-366.
[7] Inaba H, Pei D, Wolf J, et al. Infection-related complications during treatment for childhood acute lymphoblastic leukemia[J]. Ann Oncol, 2017, 28(2):386-392.
[8] Ariza-Heredia EJ, Chemaly RF. Update on infection control practices in cancer hospitals[J]. CA Cancer J Clin, 2018, 68(5):340-355.
[9] Alexander S, Fisher BT, Gaur AH, et al. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation:a randomized clinical trial[J]. JAMA, 2018, 320(10):995-1004.
[10] 闫晨华, 徐婷, 郑晓云, 等. 中国血液病患者中性粒细胞缺乏伴发热的多中心、前瞻性流行病学研究[J]. 中华血液学杂志, 2016, 37(3):177-182.
[11] Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients:2017 update[J]. J Clin Oncol, 2017, 35(18):2082-2094.
[12] Doganis D, Kafasi A, Dana H, et al. Immune response to influenza vaccination in children with cancer[J]. Hum Vaccin Immunother, 2018, 14(9):2310-2317.
[13] Hsu LY, Lee DG, Yeh SP, et al. Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific:a prospective observational study[J]. Clin Microbiol Infect, 2015, 21(6):594.e7-594.e11.
[14] Gong Y, Li C, Wang C, et al. Epidemiology and mortality-associated factors of invasive fungal disease in elderly patients:a 20-year retrospective study from southern China[J]. Infect Drug Resist, 2020, 13:711-723.
[15] Liang J, Shi P, Guo X, et al. A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia[J]. Oncol Lett, 2018, 15(1):75-82.
[16] Basile D, Di Nardo P, Corvaja C, et al. Mucosal injury during anti-cancer treatment:from pathobiology to bedside[J]. Cancers (Basel), 2019, 11(6):857.
[17] Kowalczyk JR, Zawitkowska J, Lejman M, et al, et al. Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial[J]. Am J Hematol, 2019, 94(11):E307-E310.
